Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL567659 | 1.00 | HDAC6 (0.47) | HDAC6TSHRTP53PTPN1LMNA | |
| SCHEMBL17627664 | 1.00 | HDAC6 (0.47) | HDAC6TSHRTP53PTPN1LMNA | |
| SCHEMBL30105630 | 1.00 | HDAC6 (0.47) | HDAC6TSHRTP53PTPN1LMNA | |
| SCHEMBL17689577 | 0.83 | SMN1; SMN2 (0.48) | HDAC6PTPN1ALDH1A1ALOX15 | |
| SCHEMBL19139023 | 0.80 | HDAC6 (0.41) | HDAC6PTPN1ALDH1A1ALOX15 | |
| SCHEMBL21112084 | 0.75 | CYP2C19 (0.36) | TSHRTP53PTPN1LMNAALDH1A1 | |
| SCHEMBL31199127 | 0.74 | TSHR (0.46) | TSHRTP53LMNAALDH1A1MEN1 | |
| Isocyperol SCHEMBL29477342 | 0.73 | PTPN1 (0.44) | TSHRTP53PTPN1CA1CA2 | |
| Isocyperol SCHEMBL16663911 | 0.73 | PTPN1 (0.44) | TSHRTP53PTPN1CA1CA2 | |
| SCHEMBL17627637 | 0.73 | TRPA1 (0.54) | HDAC6TSHRLMNAALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220242809-A1 | METHODS FOR ISOLATING ESSENTIAL OILS, PHYTOCHEMICALS AND PHARMACEUTICALLY ACTIVE COMPONENTS FROM BIOMASS AND RECONSTITUTING SYNTHETIC FORMULATIONS COMPRISING SAME | ATLAS HEMP COMPANY LLC (US) | 2022-08-04 | — | — | US | claimed |
| CN-122034090-A | Original-flavor cedar fragrance releasing plate and preparation method and application thereof | 北京林业大学 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026099654-A1 | COMPOSITION COMPRISING ORGANIC POLYMER AND FUNCTIONALIZED TERPENES AND METHODS OF WET ETCHING | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4731172-A2 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE NATURAL RESIN AND A CRYSTALLIZABLE FATTY SUBSTANCE | L'OREAL (FR) | 2026-04-29 | — | — | EP | disclosed |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4665318-A2 | THERAPEUTIC COMBINATIONS FOR INFLAMMATORY CONDITIONS AND DISORDERS | Native Code Bio, LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12458653-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-12427176-B2 | Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products | RIZUN NODARI (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4615240-A1 | PRODUCTION OF NATURAL GUM BASE INGREDIENTS BY PLANT CELL FERMENTATION AND APPLICATION THEREOF IN CONFECTIONERY | Wm. Wrigley Jr. Company (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2016049397-A1 | FRESHENING COMPOSITIONS AND DEVICES COMPRISING SAME | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016049395-A1 | PRODUCTS COMPRISING MALODOR REDUCTION MATERIALS | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-31 | — | — | WO | disclosed |
| US-20160090556-A1 | PRODUCTS COMPRISING MALODOR REDUCTION MATERIALS | THE PROCTER & GAMBLE COMPANY | 2016-03-31 | — | — | US | disclosed |
| WO-2016049407-A1 | ABSORBENT ARTICLE COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-31 | — | — | WO | disclosed |
| CN-103226136-B | Detection and determination method for flavor type of cigarette | HONGTA TOBACCO GROUP CO LTD | 2014-12-03 | — | — | CN | disclosed |
| CN-103226136-A | Detection and determination method for flavor type of cigarette | HONGTA TOBACCO GROUP CO LTD | 2013-07-31 | — | — | CN | disclosed |
| US-7807202-B2 | Compositions for treatment of viral-induced skin lesions and methods of using same | ECOM HEIGHTS LLC | 2010-10-05 | — | — | US | disclosed |
| US-20080131524-A1 | Mixture of tea tree oil and mineral such as selenium, iodine or silver; warts caused by the Molluscum contagiosum virus, human papillomavirus, and/or herpes simplex virus, chicken pox or shingles; does not destroy healthy, uninfected tissues, side effect reduction | SWEET NECTAR ENTERPRISES, INC. | 2008-06-05 | — | — | US | disclosed |
| US-7311928-B2 | Topical compositions containing tea tree oil for treatment of viral lesions | Tangerine Ideas, Inc. | 2007-12-25 | — | — | US | disclosed |
| US-20050123625-A1 | Compositions for treatment of viral-induced skin lesions and methods of using same | COMET CREATIONS INC. | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | CNR1, CNR2, OPRM1 | HDAC6 4518/4885TSHR 4394/4885TP53 4521/4885 |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | TRPV1, SOST, RUNX1 | HDAC6 4265/4885TSHR 3626/4885TP53 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.